Aventis Defense Against Sanofi Begins With Genasense; Ketek, Exubera Also Overlooked, Firm Says

All three brands have blockbuster potential, Aventis says. The company predicts growth of 7%-8% in 2004 revenues, but says divestments of older brands may help enhance margins.